{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:12:41Z","timestamp":1697109161590},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11894-005-0003-3","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T13:22:47Z","timestamp":1180704167000},"page":"350-357","source":"Crossref","is-referenced-by-count":8,"title":["Functional diarrhea"],"prefix":"10.1007","volume":"7","author":[{"given":"Michael J. G.","family":"Farthing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"3_CR1","first-page":"75","volume":"5","author":"WG Thompson","year":"1992","unstructured":"Thompson WG, Creed F, Drossman DA, et al.: Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992, 5:75\u201391.","journal-title":"Gastroenterol Int"},{"key":"3_CR2","first-page":"544","volume-title":"The Principles and Practice of Medicine","author":"W Osler","year":"1901","unstructured":"Osler W: Diseases of the digestive system. In The Principles and Practice of Medicine, edn 4. London: Henry Kimpton; 1901:544\u2013545.","edition":"edn 4"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/bmj.310.6973.171","volume":"310","author":"MJG Farthing","year":"1995","unstructured":"Farthing MJG: Irritable bowel, irritable body, irritable brain? BMJ 1995, 310:171\u2013175.","journal-title":"BMJ"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/gut.27.1.37","volume":"27","author":"PJ Whorwell","year":"1986","unstructured":"Whorwell PJ, McCallum M, Creed FH, et al.: Non-colonic features of irritable bowel syndrome. Gut 1986, 27:37\u201340.","journal-title":"Gut"},{"issue":"Suppl II","key":"3_CR5","first-page":"II25","volume":"45","author":"DA Drossmann","year":"1999","unstructured":"Drossmann DA, Creed FH, Olden KW, et al.: Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999, 45(Suppl II): II25-II30.","journal-title":"Gut"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/bmj.2.6138.653","volume":"11","author":"AP Manning","year":"1978","unstructured":"Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. BMJ 1978, 11:653\u2013654.","journal-title":"BMJ"},{"issue":"Suppl II","key":"3_CR7","first-page":"II43","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl II): II43-II47.","journal-title":"Gut"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2036.2004.02001.x","volume":"19","author":"BD Cash","year":"2004","unstructured":"Cash BD, Chey WD: Review article: Irritable bowel syndrome \u2014an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004, 19:1235\u20131245.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/bega.1999.0035","volume":"13","author":"R Spiller","year":"1999","unstructured":"Spiller R: Disturbances in large bowel motility. Baillieres Clin Gastroenterol 1999, 13:397\u2013413.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/bmj.299.6708.1138","volume":"299","author":"DG Maxton","year":"1989","unstructured":"Maxton DG, Morris JA, Whorwell PJ: Ranking of symptoms by patients with the irritable bowel syndrome. BMJ 1989, 299:1138.","journal-title":"BMJ"},{"key":"3_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/bega.1999.0033","volume":"13","author":"NJ Talley","year":"1999","unstructured":"Talley NJ: epidemiology. Baillieres Clin Gastroenterol 1999, 13:371\u2013384.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"3_CR12","first-page":"71","volume":"3","author":"NJ Talley","year":"1991","unstructured":"Talley NJ, Phillips SF, Bruce B, et al.: Multisystem complaints in patients with the irritable bowel syndrome and functional dyspepsia. Eur J Gastroenterol Hepatol 1991, 3:71\u201377.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.1999.01440.x","volume":"94","author":"M Schmulson","year":"1999","unstructured":"Schmulson M, Lee OY, Naliboff B, Mayer EA: Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999, 94:2929\u20132935.","journal-title":"Am J Gastroenterol"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1365-2036.2004.02250.x","volume":"20","author":"PO Vandik","year":"2004","unstructured":"Vandik PO, Wilhelmsen I, Ihlebaek C, Farup PG: Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 2004, 20:1195\u20131203. Description of the psychological and psychiatric disorders associated with IBS in a cohort of patients recruited from primary care.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 7","key":"3_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2036.2004.02184.x","volume":"20","author":"F Cremonini","year":"2004","unstructured":"Cremonini F, Talley NJ: Review article: The overlap between functional dyspepsia and irritable bowel syndrome: a tale of one or two disorders? Aliment Pharmacol Ther 2004, 20(Suppl 7):40\u201349. A comprehensive review of the relationship between IBS and functional dyspepsia. The findings of this study support the view that a significant proportion of patients have symptoms that are common to both disorders. The possibility that these disorders may have similar etiologies is discussed.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0016-5085(95)90373-9","volume":"109","author":"L Agreus","year":"1995","unstructured":"Agreus L, Svardsudd N, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995, 109:671\u2013680.","journal-title":"Gastroenterology"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1053\/gast.2002.33584","volume":"122","author":"EA Mayer","year":"2002","unstructured":"Mayer EA, Collin SM: Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002, 122:2032\u20132048. A state-of-the-art review of current thinking on the role of the brain-gut axis in the pathogenesis of functional bowel disorders.","journal-title":"Gastroenterology"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000171440","volume":"12","author":"DA Gorard","year":"1994","unstructured":"Gorard DA, Farthing MJG: Intestinal motor function in irritable bowel syndrome. Dig Dis Sci 1994, 12:72\u201374.","journal-title":"Dig Dis Sci"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1542-3565(03)00291-X","volume":"2","author":"M Corsetti","year":"2004","unstructured":"Corsetti M, Cesana B, Bhoori S, Basilisco G: Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. Clin Gastroenterol Hepatol 2004, 2:49\u201356. Important primary research study that helps refine the technique of rectal distention by balloon inflation for assessing rectal sensation in humans.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/gut.31.4.458","volume":"31","author":"A Prior","year":"1990","unstructured":"Prior A, Maxton DG, Whorwell PJ: Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990, 31:458\u2013462.","journal-title":"Gut"},{"key":"3_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2036.2003.01486.x","volume":"17","author":"R Lea","year":"2003","unstructured":"Lea R, Houghton LA, Calvert EL, et al.: Gut-focused hypnotherapy normalizes disordered sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:635\u2013642. This investigation adds to the literature on the value of hypnotherapy in the treatment of IBS by demonstrating that it not only has effects on IBS symptoms but is also able to modulate visceral hypersensitivity.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000201377","volume":"57","author":"PA Goldberg","year":"1996","unstructured":"Goldberg PA, Kamm MA, Setti-Carraro P, et al.: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996, 57:478\u2013483.","journal-title":"Digestion"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.47.6.861","volume":"47","author":"EA Mayer","year":"2000","unstructured":"Mayer EA: The neurobiology of stress and gastrointestinal disease. Gut 2000, 47:861\u2013869.","journal-title":"Gut"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0016-5085(03)00324-X","volume":"124","author":"RC Spiller","year":"2003","unstructured":"Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662\u20131672. An authoritative review of the role of intestinal infection in the production of IBS symptoms. It highlights the particular importance of enterochromaffin cells, 5-HT, and persistent microscopic inflammation.","journal-title":"Gastroenterology"},{"key":"3_CR25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.47.6.804","volume":"47","author":"RC Spiller","year":"2000","unstructured":"Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804\u2013811.","journal-title":"Gut"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/bega.1999.0038","volume":"13","author":"BN Gaynes","year":"1999","unstructured":"Gaynes BN, Drossman DA: The role of psychosocial factors in irritable bowel syndrome. Baillieres Clin Gastroenterol 1999, 13:437\u2013452.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/gut.28.10.1307","volume":"28","author":"F Creed","year":"1987","unstructured":"Creed F, Guthrie E: Psychological factors in the irritable bowel syndrome. Gut 1987, 28:1307\u20131318.","journal-title":"Gut"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/gut.28.2.160","volume":"28","author":"MJ Ford","year":"1987","unstructured":"Ford MJ, Miller PM, Eastwood J, Eastwood MA: Life events, psychiatric illness and the irritable bowel syndrome. Gut 1987, 28:160\u2013165.","journal-title":"Gut"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0033-3182(93)71884-8","volume":"34","author":"RB Lydiard","year":"1993","unstructured":"Lydiard RB, Fossey MD, Marsh W, Ballenger JC: Prevalence of psychiatric disorders in patients with the irritable bowel syndrome. Psychosomatics 1993, 34:229\u2013234.","journal-title":"Psychosomatics"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/gast.2002.33579","volume":"122","author":"VS Chadwick","year":"2002","unstructured":"Chadwick VS, Chen W, Shu D, et al.: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778\u20131783. This report describes a detailed study of colonic mucosal inflammatory changes in patients presenting with Rome I criteria IBS. It indicates that up to 10% of patients may have lymphocytic colitis and a further 44% had nonspecific microscopic inflammation of uncertain significance.","journal-title":"Gastroenterology"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","volume":"31","author":"PS Efskind","year":"1996","unstructured":"Efskind PS, Bernklev T, Vatn MH: A double-blind placebocontrolled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996, 31:463\u2013468.","journal-title":"Scand J Gastroenterol"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-133-2-200007180-00013","volume":"133","author":"J Jaiwala","year":"2000","unstructured":"Jaiwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136\u2013147.","journal-title":"Ann Intern Med"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2036.1994.tb00322.x","volume":"8","author":"T Poynard","year":"1994","unstructured":"Poynard T, Naveau S, Mory B, et al.: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8:499\u2013510.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","volume":"15","author":"T Poynard","year":"2001","unstructured":"Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355\u2013361.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gut.28.4.423","volume":"28","author":"PJ Whorwell","year":"1987","unstructured":"Whorwell PJ, Prior A, Colgan SM: Hypnotherapy in severe irritable bowel syndrome, further experience. Gut 1987, 28:423\u2013425.","journal-title":"Gut"},{"key":"3_CR36","first-page":"277","volume":"91","author":"NJ Talley","year":"1996","unstructured":"Talley NJ, Owen BK, Boyce P, Paterson K: Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996, 91:277\u2013283.","journal-title":"Am J Gastroenterol"},{"key":"3_CR37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0016-5085(88)90319-8","volume":"95","author":"KB Klein","year":"1977","unstructured":"Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1977, 95:232\u2013241.","journal-title":"Gastroenterology"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/gut.48.2.272","volume":"48","author":"R Akehurst","year":"2001","unstructured":"Akehurst R, Kaltenthaler E: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001, 48:272\u2013283.","journal-title":"Gut"},{"key":"3_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9343(99)00299-5","volume":"108","author":"JL Jackson","year":"2000","unstructured":"Jackson JL, O\u2019Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65\u201372.","journal-title":"Am J Med"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF02063948","volume":"40","author":"DA Gorard","year":"1995","unstructured":"Gorard DA, Libby GW, Farthing MJG: Effect of a tricyclic anti-depressant on small intestinal motility in health and in diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995, 40:86\u201395.","journal-title":"Dig Dis Sci"},{"key":"3_CR41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.35.4.496","volume":"34","author":"DA Gorard","year":"1994","unstructured":"Gorard DA, Libby GW, Farthing MJG: 5 hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine uptake. Gut 1994, 34:496\u2013500.","journal-title":"Gut"},{"key":"3_CR42","first-page":"59","volume-title":"Basic Mechanisms of Digestive Diseases: The Rationale for Clinical Management and Prevention","author":"MJG Farthing","year":"2002","unstructured":"Farthing MJG: Irritable bowel syndrome: new drugs and therapeutic horizons. In Basic Mechanisms of Digestive Diseases: The Rationale for Clinical Management and Prevention. Edited by Farthing MJG, Malfertheiner P. Paris: John Libbey Eurotext; 2002:59\u201373."},{"key":"3_CR43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199856010-00002","volume":"56","author":"MJG Farthing","year":"1998","unstructured":"Farthing MJG: New drugs in the management of the irritable bowel syndrome. Drugs 1998, 56:11\u201321.","journal-title":"Drugs"},{"key":"3_CR44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/bega.1999.0040","volume":"13","author":"MJG Farthing","year":"1999","unstructured":"Farthing MJG: Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Clin Gastroenterol 1999, 13:461\u2013471.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"3_CR45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.42.1.42","volume":"42","author":"CP Bearcroft","year":"1998","unstructured":"Bearcroft CP, Perrett D, Farthing MJG: Post-prandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome. Gut 1998, 42:42\u201346.","journal-title":"Gut"},{"key":"3_CR46","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/gut.52.5.663","volume":"52","author":"LA Houghton","year":"2003","unstructured":"Houghton LA, Atkinson W, Whitaker P, et al.: Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52:1799\u2013800.","journal-title":"Gut"},{"issue":"Suppl III","key":"3_CR47","first-page":"A 210","volume":"47","author":"M Bose","year":"2000","unstructured":"Bose M, Nickols C, Feakins R, et al.: A comparison of 5-hydroxytryptamine staining in enterochromaffin cells between irritable bowel syndrome and other gastrointestinal disorders. Gut 2000, 47(Suppl III):A 210.","journal-title":"Gut"},{"key":"3_CR48","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","volume":"355","author":"M Camilleri","year":"2000","unstructured":"Camilleri M, Nortcutt AR, Kong S, et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035\u20131040.","journal-title":"Lancet"},{"key":"3_CR49","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","volume":"161","author":"M Camilleri","year":"2001","unstructured":"Camilleri M, Chey WY, Mayer EA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733\u20131740.","journal-title":"Arch Intern Med"},{"key":"3_CR50","doi-asserted-by":"crossref","unstructured":"Rabasseda X, Leeson P, Silvestre J, Castaner J: Cilansetron: drugs of the future 1999, 24:475\u2013482.","DOI":"10.1358\/dof.1999.024.05.489133"},{"issue":"suppl 1","key":"3_CR51","doi-asserted-by":"crossref","first-page":"A148","DOI":"10.1016\/S0016-5085(03)80736-9","volume":"124","author":"P Holzer","year":"2003","unstructured":"Holzer P, Painsipp E, Weber E, et al.: 5-HT3 receptor antagonists, alosetron and cilansetron impair mesenteric blood flow in rats. Gastroenterology 2003, 124(suppl 1):A148-A149.","journal-title":"Gastroenterology"},{"key":"3_CR52","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","volume":"95","author":"M Pimental","year":"2000","unstructured":"Pimental M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503\u20133506.","journal-title":"Am J Gastroenterol"},{"key":"3_CR53","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00042737-200110000-00004","volume":"13","author":"K Niedzielin","year":"2001","unstructured":"Niedzielin K: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13:1143\u20131147.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3_CR54","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","volume":"128","author":"L O\u2019Mahoney","year":"2005","unstructured":"O\u2019Mahoney L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541\u2013551. A randomized controlled clinical trial of two probiotic preparations in patients with IBS. Clinical improvement was also associated with reduction in proinflammatory cytokine production.","journal-title":"Gastroenterology"},{"key":"3_CR55","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/089106001753341282","volume":"3","author":"JMT Hamilton-Miller","year":"2001","unstructured":"Hamilton-Miller JMT: Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microbial Ecol Health Dis 2001, 3:212\u2013216.","journal-title":"Microbial Ecol Health Dis"},{"key":"3_CR56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.2003.01640.x","volume":"18","author":"SP Dunlop","year":"2003","unstructured":"Dunlop SP, Jenkins D, Neal KR, et al.: Randomized, doubleblind placebo-controlled trial of prednisolone in postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77\u201384. A randomized controlled clinical trial of prednisolone versus placebo in post-infectious IBS. There was no improvement in symptoms in the active treatment group.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR57","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.280.18.1585","volume":"280","author":"A Bensoussan","year":"1998","unstructured":"Bensoussan A, Talley NJ, Hing M, et al.: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998, 280:1585\u20131589.","journal-title":"JAMA"},{"key":"3_CR58","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1365-2036.2004.02242.x","volume":"20","author":"JJ Sung","year":"2004","unstructured":"Sung JJ, Leung WK, Ching JY, et al.: Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:1205\u20131210.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2036.2004.01859.x","volume":"19","author":"A Madisch","year":"2004","unstructured":"Madisch A, Holtmann G, Plein K, Hotz J: Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled multi-centre trial. Aliment Pharmacol Ther 2004, 19:271\u2013279. A randomized controlled clinical trial of herbal preparations in IBS. This preliminary study reported some encouraging results.","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.aje.a116483","volume":"136","author":"NJ Talley","year":"1992","unstructured":"Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III: Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992, 136:165\u2013177.","journal-title":"Am J Epidemiol"},{"key":"3_CR61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2036.2004.01929.x","volume":"19","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Pilgrim P, Schoenfeld: Systematic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 19:861\u2013870. A comprehensive systematic review of how IBS symptoms fluctuate with time. This is an important contribution to the literature on the prognosis of IBS.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0003-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-005-0003-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-005-0003-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:03:51Z","timestamp":1559433831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-005-0003-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11894-005-0003-3","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}